Stone Ridge Asset Management LLC Acquires Shares of 56,590 Diplomat Pharmacy (NYSE:DPLO)

Stone Ridge Asset Management LLC purchased a new stake in Diplomat Pharmacy (NYSE:DPLO) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 56,590 shares of the company’s stock, valued at approximately $1,136,000. Stone Ridge Asset Management LLC owned approximately 0.08% of Diplomat Pharmacy at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Advisors Preferred LLC purchased a new stake in shares of Diplomat Pharmacy in the fourth quarter valued at approximately $162,000. SG Americas Securities LLC purchased a new stake in shares of Diplomat Pharmacy in the third quarter valued at approximately $191,000. Piedmont Investment Advisors LLC purchased a new stake in shares of Diplomat Pharmacy in the third quarter valued at approximately $216,000. Fox Run Management L.L.C. purchased a new stake in shares of Diplomat Pharmacy in the fourth quarter valued at approximately $244,000. Finally, ETRADE Capital Management LLC purchased a new stake in shares of Diplomat Pharmacy in the fourth quarter valued at approximately $276,000. Institutional investors and hedge funds own 64.64% of the company’s stock.

How to Become a New Pot Stock Millionaire

Diplomat Pharmacy stock traded down $0.42 during mid-day trading on Friday, hitting $19.72. The company’s stock had a trading volume of 499,137 shares, compared to its average volume of 845,807. The firm has a market capitalization of $1,460.64, a price-to-earnings ratio of 23.48 and a beta of 1.32. Diplomat Pharmacy has a 1 year low of $14.00 and a 1 year high of $27.78. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.66 and a current ratio of 0.97.

Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.02. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.17 billion. Diplomat Pharmacy had a return on equity of 8.89% and a net margin of 0.35%. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.08 earnings per share. analysts forecast that Diplomat Pharmacy will post 0.94 EPS for the current year.

In other Diplomat Pharmacy news, Director Philip R. Hagerman sold 2,150,000 shares of the company’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $20.65, for a total transaction of $44,397,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 30.20% of the stock is owned by corporate insiders.

A number of research firms have recently issued reports on DPLO. Barclays began coverage on Diplomat Pharmacy in a research report on Thursday, March 8th. They issued an “overweight” rating and a $27.00 price target for the company. Deutsche Bank lowered Diplomat Pharmacy from a “buy” rating to a “hold” rating and upped their price target for the company from $22.00 to $29.00 in a research report on Friday, February 2nd. Lake Street Capital began coverage on Diplomat Pharmacy in a research report on Friday, February 9th. They issued a “buy” rating and a $35.00 price target for the company. Credit Suisse Group upgraded Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 price target for the company in a research report on Thursday, January 25th. Finally, Leerink Swann set a $30.00 price target on Diplomat Pharmacy and gave the company a “buy” rating in a research report on Tuesday, February 27th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $25.38.

WARNING: “Stone Ridge Asset Management LLC Acquires Shares of 56,590 Diplomat Pharmacy (NYSE:DPLO)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/08/stone-ridge-asset-management-llc-takes-position-in-diplomat-pharmacy-inc-dplo.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply